Supernus, Inc. (SUPN)
Health Care ยท Pharmaceutical Preparations
Supernus, Inc. (SUPN) is listed on Nasdaq, where its shares have traded since May 1, 2012. SentiSense covers Supernus, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Jack Khattar is its chief executive officer. The company reports 778 employees, and its corporate website is www.supernus.com.
About Supernus, Inc.
Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Latest reported results
Supernus Pharmaceuticals Inc. reported revenue of $356.0 million for Q3 FY2026, up 13.4% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 323 institutions reported holding SUPN, with 60.1 million shares worth $2.8 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Millennium Management. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on SUPN
- SUPN sentiment: whether news and social coverage of Supernus, Inc. leans bullish or bearish, and the stories driving it.
- SUPN ownership: all 323 reporting institutions, plus insider and congressional trades.
- SUPN financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Supernus, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Supernus, Inc. do?
Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.
What sector is SUPN in?
SentiSense classifies Supernus, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does SUPN stock trade?
Supernus, Inc. (SUPN) is listed on Nasdaq, where its shares have traded since May 1, 2012.
Who is the CEO of Supernus, Inc.?
Jack Khattar is the chief executive officer of Supernus, Inc..